Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

Diabetic Medicine

Volumn 25, Issue 2, 2008, Pages 152-156

  Vilsboll T ^a   Brock, B ^b   Perrild, H ^c   Levin, K ^c   Lervang, H H ^d   Kolendorf K ^e   Krarup, T ^a   Schmitz, O ^b   Zdravkovic, M ^f   Le Thi, T ^f   Madsbad, S ^g  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e Roskilde Amts Roskilde ^*  (Denmark)

^f NOVO NORDISK A S   (Denmark)

^g HVIDOVRE HOSPITAL   (Denmark)

Author keywords

B cell function; Clinical trial; Glucagon like peptide 1; Insulin secretion; Liraglutide

Indexed keywords

ARGININE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; LIRAGLUTIDE; PLACEBO;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FREQUENCY ANALYSIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 39749143348     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02333.x     Document Type: Article

References (20)

1. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003 52 : 102 110.
2. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B-cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1984 74 : 1318 1328.
3. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med 2005 22 : 1016 1023.
4. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004 27 : 1335 1342.
5. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006 114 : 417 423.
6. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. The effect of NN2211, a long acting GLP1 derivative on glycemic control and body weight in obese patients with Type 2 diabetes. Diabet Med 22 : 1016 1023.
7. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007 30 : 1608 1610.
8. Bock T, Pakkenberg B, Buschard K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 2003 111 : 1117 1124.
9. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002 283 : E745 E752.
10. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003 140 : 123 132.
11. Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen FB, Tornhave D et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005 330 : 577 584.
12. Piper K, Dijkstra I, Dunleavey L, Hanley N. The long-acting GLP-1 analog, liraglutide, increases beta cell numbers during early human development. Diabetes 2005 54 : Abstract A394.
13. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004 53 : 1187 1194.
14. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003 52 : 1786 1791.
15. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987 79 : 790 800.
16. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992 130 : 159 166.
17. Fehmann HC, Gherzi R, Goke B. Regulation of islet hormone gene expression by incretin hormones. Exp Clin Endocrinol Diabetes 1995 103 : 56 65.
18. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002 143 : 339 342.
19. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005 90 : 5991 5997.
20. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002 51 : 424 429.